阿帕替尼联合放化疗治疗非小细胞肺癌脑转移患者的近期疗效与安全性

HFCAS OpenIR

	阿帕替尼联合放化疗治疗非小细胞肺癌脑转移患者的近期疗效与安全性
其他题名	Short-term efficacy and safety of apatinib combined with chemoradiotherapy in treatment of NSCLC patients with brain metastases
	尹雪 1; 胡宗涛 1; 徐秀理 1; 张文康 1; 崔相利1 ; 高世乐 2
	2020
发表期刊	中国肿瘤生物治疗杂志
ISSN	1007-385X
摘要	目的:观察阿帕替尼联合放疗同步多西他赛与顺铂化疗治疗驱动基因阴性非小细胞肺癌(NSCLC)脑转移瘤患者的近期疗效和安全性。方法:收集2018年6月至2019年6月在我院收治的NSCLC脑转移患者72例,二代基因测序(NGS)显示驱动基因阴性,数字随机分组法分为对照组36例、治疗组36例,对照组接受多西他赛、顺铂方案化疗2个周期及同步脑转移瘤放疗,治疗组在观察组基础上给予阿帕替尼抗血管生成治疗。主要研究终点:确认有效率(cORR)和疾病控制率(DCR);次要研究终点:无进展生存期(PFS),生存质量(QOL)评分,血清癌胚抗原(CEA),血管内皮生长因子(VEGF)及药物不良事件(AE)发生率。结果:与对照组相比,治疗组cORR和DCR明显提高41.67%(15/36)vs 33.33%(12/36)、80.56%(29/36)vs 69.44%(25/36),均P 0.05)。两组患者在急性脑水肿、胃肠反应、骨髓抑制、肝功能减退发生率的差异无统计学意义(均P>0.05),治疗组口腔黏膜炎、手足综合征、高血压、蛋白尿发生率明显高于对照组(均P<0.05)。结论:阿帕替尼联合放化疗在驱动基因阴性NSCLC脑转移患者中的疗效明显优于单纯放化疗,且不良反应可控,值得临床推荐。
其他摘要	Objective:To observe the short-term efficacy and safety of Apatinib combined with radiotherapy and concurrent docetaxel and cisplatin chemotherapy in driver-gene-negative non-small cell lung cancer(NSCLC)patients with brain metastases.Methods:A total of 72 NSCLC patients with brain metastases,who were treated in our hospital from June 2018 to June 2019,were enrolled in this study.The driver gene was proved to be negative by next generation sequencing(NGS).The patients were divided into control group(36 cases)and treatment group(36 cases)by Digital random grouping method.The control group received 2 cycles of chemotherapy with docetaxel and cisplatin and concurrent radiotherapy for brain metastases,and the treatment group was given Apatinib anti-angiogenic treatment based on the regimen in control group.Primary study endpoints:confirmed objective response rate(cORR)and disease control rate(DCR);Secondary study endpoints:progression-free survival(PFS),quality of life(QOL)score,serum carcinoembryonic antigen(CEA),vascular endothelial growth factor(VEGF),and incidence of adverse drug events(AE).Results:Compared with the control group,cORR and DCR in treatment group were significantly improved41.67%(15/36)vs 33.33%(12/36),80.56%(29/36)vs 69.44%(25/36),all P 0.05.There was no statistically significant difference in the incidence of acute brain edema,gastrointestinal reaction,bone marrow suppression,and liver dysfunction between the two groups of patients(all P>0.05);however,the incidences of oral mucositis,hand-foot syndrome,hypertension and proteinuria in the treatment group were significantly higher than those in the control group(all P<0.05).Conclusion:The efficacy of Apatinib combined with radiochemotherapy in driver-negative NSCLC patients with brain metastases is significantly better than that of radiochemotherapy alone,and the adverse reactions can be controlled.It is worthy of clinical recommendation.
关键词	non-small cell lung cancer (NSCLC) brain metastasis apatinib concurrent radiochemotherapy short-term efficacy safety 非小细胞肺癌脑转移阿帕替尼同步放化疗近期疗效安全性
收录类别	CSCD
语种	中文
CSCD记录号	CSCD:6746323
引用统计	被引频次：1[CSCD] [CSCD记录]
文献类型	期刊论文
条目标识符	http://ir.hfcas.ac.cn:8080/handle/334002/46835
专题	中国科学院合肥物质科学研究院
作者单位	1.中国科学院合肥肿瘤医院放疗部 2.中国科学院合肥肿瘤医院放疗部 3.中国科学院合肥肿瘤医院放疗部 4.中国科学院合肥肿瘤医院放疗部 5.中国科学院合肥肿瘤医院放疗部 6.中国人民解放军联勤保障部队第九〇一医院肿瘤四科
推荐引用方式 GB/T 7714	尹雪,胡宗涛,徐秀理,等. 阿帕替尼联合放化疗治疗非小细胞肺癌脑转移患者的近期疗效与安全性[J]. 中国肿瘤生物治疗杂志,2020,27.
APA	尹雪,胡宗涛,徐秀理,张文康,崔相利,&高世乐.(2020).阿帕替尼联合放化疗治疗非小细胞肺癌脑转移患者的近期疗效与安全性.中国肿瘤生物治疗杂志,27.
MLA	尹雪,et al."阿帕替尼联合放化疗治疗非小细胞肺癌脑转移患者的近期疗效与安全性".中国肿瘤生物治疗杂志 27(2020).